Amgen Inc. (AMGN) to Issue Quarterly Dividend of $2.52 on September 11th

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Thursday, July 30th. Shareholders of record on Friday, August 21st will be given a dividend of 2.52 per share by the medical research company on Friday, September 11th. This represents a c) annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st.

Amgen has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 14 consecutive years. Amgen has a payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $23.86 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 42.2%.

Amgen Stock Down 0.6%

Amgen stock opened at $385.16 on Friday. The business’s 50-day simple moving average is $356.60 and its two-hundred day simple moving average is $353.77. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $207.87 billion, a PE ratio of 26.80, a PEG ratio of 3.92 and a beta of 0.41. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $398.00.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. Equities analysts anticipate that Amgen will post 22.31 EPS for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.